Norovirus vaccine recombinant monovalent - Takeda

Drug Profile

Norovirus vaccine recombinant monovalent - Takeda

Alternative Names: Norovirus dry powder vaccine - Takeda; Norovirus monovalent VLP vaccine - Takeda; Norwalk virus-like particle vaccine - Takeda

Latest Information Update: 21 Sep 2015

Price : $50

At a glance

  • Originator LigoCyte Pharmaceuticals
  • Developer Baylor College of Medicine; Takeda
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Norovirus infections

Most Recent Events

  • 05 Aug 2014 Archimedes Pharma has been acquired by ProStrakan
  • 05 Oct 2012 LigoCyte Pharmaceuticals has been acquired and merged into Takeda
  • 25 Oct 2010 Efficacy & adverse events data from the phase I/II LV01-103 trial in Norovirus infections presented at the (48th Annual Meeting of the Infectious Diseases Society of America (IDSA-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top